GLP-1 receptor agonist matches surgical levels of weight loss: trial

Phase 3 results for tirzepatide show a third of patients on 15mg weekly dose had a 25% reduction in weight

A novel anti-obesity drug could see patients lose more than a quarter of their body weight in one to two years — an amount comparable to bariatric surgery — US research reports.

Results from a phase 3 trial of tirzepatide found that one in three participants with a BMI of more than 30, but no diabetes, saw a 25% reduction in weight on a 15mg dose.

The drug regimen involved subcutaneous injections over 72 weeks with a 20-week dose escalation period, according to the study that concluded an “unusually” high degree of